Document is current
Any future updates will be listed below
-
Authors
Phillips, Aaron F.
Zhang, Rumin
Jaffe, Mia
Schulz, Ryan
Carty, Marysol Chu https://orcid.org/0009-0000-5347-9367
Verma, Akanksha
Feinberg, Tamar Y.
Arensman, Michael D.
Chiu, Alan
Letso, Reka
Bosco, Nazario
Queen, Katelyn A.
Racela, Allison R.
Stumpff, Jason https://orcid.org/0000-0003-0392-1254
Andreu-Agullo, Celia
Bettigole, Sarah E.
Depetris, Rafael S.
Drutman, Scott
Su, Shinsan M.
Cogan, Derek A.
Eng, Christina H. https://orcid.org/0009-0009-9860-6505
-
Funding
Funding for this research was provided by:
National Science Foundation (GRF 1842491)
U.S. Department of Health & Human Services | National Institutes of Health (R35 GM144133)
- License Information
-
More Information
Article History
Received: 28 February 2023
Accepted: 5 December 2024
First Online: 2 January 2025
Competing interests
: A.F.P., R.Z., M.J., R.S., M.C.C., A.V., T.Y.F., M.D.A., A.C., R.L., N.B., C.A-A., S.E.B., R.S.D., S.D., S.M.S., D.A.C. and C.H.E. are current or former employees of Volastra Therapeutics and may own equity in Volastra Therapeutics. J.S. received funding from Volastra Therapeutics. D.A.C. is an inventor on a patent (WO/2023/028564) filed by Volastra Therapeutics describing KIF18A inhibitors including VLS-1272. D.A.C., S.M.S. and S.D. are inventors on a patent (WO/2024/178255) filed by Volastra Therapeutics describing formulations of KIF18A inhibitors including VLS-1272.
